# Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma

> **NCT05861778** · PHASE1 · COMPLETED · sponsor: **Telix Pharmaceuticals (Innovations) Pty Limited** · enrollment: 10 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Suspected Recurrent Renal Clear Cell Carcinoma
- Recurrent Renal Cell Cancer

## Interventions

- **DRUG:** 89Zr-Girentuximab

## Key facts

- **NCT ID:** NCT05861778
- **Lead sponsor:** Telix Pharmaceuticals (Innovations) Pty Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-26
- **Primary completion:** 2023-11-27
- **Final completion:** 2023-11-27
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2023-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05861778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05861778, "Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05861778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*